BRPI1011453A2 - formulacao, forma de dosagem de um medicamento, e, sal de hemipamoato de asenapina - Google Patents
formulacao, forma de dosagem de um medicamento, e, sal de hemipamoato de asenapinaInfo
- Publication number
- BRPI1011453A2 BRPI1011453A2 BRPI1011453A BRPI1011453A BRPI1011453A2 BR PI1011453 A2 BRPI1011453 A2 BR PI1011453A2 BR PI1011453 A BRPI1011453 A BR PI1011453A BR PI1011453 A BRPI1011453 A BR PI1011453A BR PI1011453 A2 BRPI1011453 A2 BR PI1011453A2
- Authority
- BR
- Brazil
- Prior art keywords
- formulation
- drug
- dosage form
- asenapine hemipamoate
- hemipamoate salt
- Prior art date
Links
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 title 1
- 229960005245 asenapine Drugs 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22002709P | 2009-06-24 | 2009-06-24 | |
| PCT/EP2010/058960 WO2010149727A2 (en) | 2009-06-24 | 2010-06-24 | Injectable formulations containing asenapine and method of treatment using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1011453A2 true BRPI1011453A2 (pt) | 2016-03-15 |
Family
ID=43386952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1011453A BRPI1011453A2 (pt) | 2009-06-24 | 2010-06-24 | formulacao, forma de dosagem de um medicamento, e, sal de hemipamoato de asenapina |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8658687B2 (pt) |
| EP (1) | EP2453870A2 (pt) |
| JP (1) | JP5801295B2 (pt) |
| KR (1) | KR101435296B1 (pt) |
| CN (1) | CN102596172A (pt) |
| AR (1) | AR077225A1 (pt) |
| AU (1) | AU2010264670A1 (pt) |
| BR (1) | BRPI1011453A2 (pt) |
| CA (1) | CA2766291C (pt) |
| MX (1) | MX2012000061A (pt) |
| RU (1) | RU2012102247A (pt) |
| TW (1) | TW201113018A (pt) |
| WO (1) | WO2010149727A2 (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2524920A1 (en) | 2011-05-17 | 2012-11-21 | Sandoz AG | Novel Crystalline Asenapine Hydrochloride Salt Forms |
| EP2524921A1 (en) * | 2011-05-17 | 2012-11-21 | Sandoz AG | Novel Crystalline Salts of Asenapine |
| JO3421B1 (ar) | 2011-06-20 | 2019-10-20 | H Lundbeck As | طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية |
| EP2878299B1 (en) * | 2012-07-26 | 2018-05-16 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch |
| BR112015009839A2 (pt) * | 2012-11-01 | 2017-07-11 | Torrent Pharmaceuticals Ltd | composição farmacêutica de tapentadol para administração parenteral |
| FR3020810B1 (fr) * | 2014-05-06 | 2016-05-06 | Servier Lab | Nouveau sel de l'ivabradine et son procede de preparation. |
| CA2987081C (en) | 2015-06-11 | 2022-08-30 | Alrise Biosystems Gmbh | Process for the preparation of drug loaded microparticles |
| CN110087641B (zh) | 2016-12-20 | 2024-03-12 | 罗曼治疗系统股份公司 | 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统 |
| PL3338768T3 (pl) | 2016-12-20 | 2020-05-18 | Lts Lohmann Therapie-Systeme Ag | Transdermalny system terapeutyczny zawierający asenapinę |
| US10933014B2 (en) * | 2017-01-09 | 2021-03-02 | Asarina Pharma Ab | Injectable suspension comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, and a method for the manufacturing thereof |
| JP2020525545A (ja) | 2017-06-26 | 2020-08-27 | エルテーエス ローマン テラピー−ジステーメ アーゲー | アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム |
| ES2970570T3 (es) * | 2017-11-07 | 2024-05-29 | Intervet Int Bv | Composiciones farmacéuticas inyectables de isoxazolina y su uso contra una infestación por parásitos |
| EP3707129A1 (en) | 2017-11-07 | 2020-09-16 | Intervet International B.V. | Process for preparing large size isoxazoline particles |
| BR112020026099A2 (pt) | 2018-06-20 | 2021-03-23 | Lts Lohmann Therapie-Systeme Ag | sistema terapêutico transdérmico que contém asenapina |
| CN118806732A (zh) | 2018-06-20 | 2024-10-22 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| US20230355612A1 (en) * | 2020-08-26 | 2023-11-09 | Shanghai Bocimed Pharmaceutical Co., Ltd. | Pharmaceutically acceptable salt of cariprazine and crystal form thereof, and preparation method therefor and use thereof |
| CN116675654B (zh) * | 2022-02-22 | 2025-06-13 | 上海云晟研新生物科技有限公司 | 卡利拉嗪药用盐及其晶型、药物组合物、制备方法和用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7605526A (nl) * | 1976-05-24 | 1977-11-28 | Akzo Nv | Nieuwe tetracyclische derivaten. |
| ZA933134B (en) * | 1992-05-08 | 1993-11-30 | Akzo Nv | Depot preparation |
| EP0569096A1 (en) | 1992-05-08 | 1993-11-10 | Akzo Nobel N.V. | Depot preparation |
| ATE167057T1 (de) | 1994-03-02 | 1998-06-15 | Akzo Nobel Nv | Sublinguales oder bukkales arzneimittel |
| AU7767598A (en) * | 1997-05-26 | 1998-12-30 | Akzo Nobel N.V. | Salts of aromatic sulphonic acids |
| AU752552C (en) | 1997-09-30 | 2003-09-11 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine formulation |
| US6617321B2 (en) | 1997-09-30 | 2003-09-09 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine formulation |
| MX2007004485A (es) * | 2004-10-15 | 2007-06-13 | Organon Nv | Tratamiento de desordenes bipolares y sintomas asociados. |
| KR101422843B1 (ko) * | 2005-04-07 | 2014-07-24 | 머크 샤프 앤 도메 비.브이. | 아세나핀 말레에이트의 결정형 |
| AU2006231281B2 (en) * | 2005-04-07 | 2011-04-28 | Msd Oss B.V. | Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole |
| TW200817414A (en) | 2006-07-05 | 2008-04-16 | Organon Nv | Process for the preparation of asenapine and intermediate products used in said process |
| WO2009087058A1 (en) | 2008-01-04 | 2009-07-16 | N.V. Organon | Process for the preparation of asenapine and intermediate products used in said process |
-
2010
- 2010-06-24 KR KR1020127001815A patent/KR101435296B1/ko active Active
- 2010-06-24 AR ARP100102242A patent/AR077225A1/es not_active Application Discontinuation
- 2010-06-24 CA CA2766291A patent/CA2766291C/en not_active Expired - Fee Related
- 2010-06-24 BR BRPI1011453A patent/BRPI1011453A2/pt not_active Application Discontinuation
- 2010-06-24 AU AU2010264670A patent/AU2010264670A1/en not_active Abandoned
- 2010-06-24 WO PCT/EP2010/058960 patent/WO2010149727A2/en not_active Ceased
- 2010-06-24 CN CN2010800378161A patent/CN102596172A/zh active Pending
- 2010-06-24 US US13/378,118 patent/US8658687B2/en not_active Expired - Fee Related
- 2010-06-24 JP JP2012516732A patent/JP5801295B2/ja active Active
- 2010-06-24 EP EP10725792A patent/EP2453870A2/en not_active Withdrawn
- 2010-06-24 TW TW099120654A patent/TW201113018A/zh unknown
- 2010-06-24 RU RU2012102247/15A patent/RU2012102247A/ru unknown
- 2010-06-24 MX MX2012000061A patent/MX2012000061A/es not_active Application Discontinuation
-
2013
- 2013-12-17 US US14/109,633 patent/US20140154322A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP5801295B2 (ja) | 2015-10-28 |
| KR20120030561A (ko) | 2012-03-28 |
| US20120237561A1 (en) | 2012-09-20 |
| CA2766291C (en) | 2016-06-21 |
| JP2012530759A (ja) | 2012-12-06 |
| EP2453870A2 (en) | 2012-05-23 |
| AU2010264670A1 (en) | 2012-01-19 |
| US20140154322A1 (en) | 2014-06-05 |
| WO2010149727A2 (en) | 2010-12-29 |
| RU2012102247A (ru) | 2013-07-27 |
| KR101435296B1 (ko) | 2014-08-27 |
| TW201113018A (en) | 2011-04-16 |
| CA2766291A1 (en) | 2010-12-29 |
| US8658687B2 (en) | 2014-02-25 |
| MX2012000061A (es) | 2012-06-01 |
| AR077225A1 (es) | 2011-08-10 |
| WO2010149727A3 (en) | 2011-04-21 |
| CN102596172A (zh) | 2012-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301291I2 (nl) | sparsentan of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301248I2 (nl) | atogepant of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301157I2 (nl) | odevixibat of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301187I2 (nl) | Rimegepant of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301035I2 (nl) | upadacitinib of een farmaceutisch aanvaardbaar zout daarvan | |
| BRPI0906467A2 (pt) | forma de dose farmacêutica | |
| NL300901I2 (nl) | pibrentasvir of een farmaceutisch aanvaardbaar zout daarvan | |
| SMT201500209B (it) | Forme di dosaggio farmaceutiche a rilascio controllato | |
| IL245328A0 (en) | Pharmaceutical composition | |
| IL229409B (en) | Intranasal pharmaceutical dosage forms comprising naloxone | |
| ZA201304709B (en) | A pharmaceutical dosage form | |
| BR112015003376A2 (pt) | composto ou sal farmaceuticamente aceitável do mesmo , composição farmacêutica e usos de quantidade eficiente | |
| BR112012011902A2 (pt) | cápsula farmacêutica | |
| IL219276A0 (en) | Gastroretentive dosage forms of poorly soluble drugs | |
| BRPI1012246A2 (pt) | composição farmacêutica contendo um fármaco e sirna | |
| DK2652652T3 (da) | Medikmentadministration | |
| EP2568979A4 (en) | RATIOMETRIC COMBINATORY MEDICINE ADMINISTRATION | |
| SI2582366T1 (sl) | Farmacevtska kombinacija za zdravljenje bolečine | |
| BR112014003802A2 (pt) | composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento | |
| IL231622B (en) | Pharmaceutical composition for treatment of cachexia | |
| BRPI1005433A2 (pt) | preparações farmacêuticas transdérmicas | |
| BRPI0922653A2 (pt) | preparação farmacêutica | |
| DK2437736T3 (da) | Lægemiddelindgivelsessystemer | |
| PL2665471T3 (pl) | Doustne farmaceutyczne postacie dawkowane o kontrolowanym uwalnianiu zawierające mgbg | |
| BR112012031102A2 (pt) | forma de dosagem oral sólida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A E 6A ANUIDADES |
|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |